Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
$5.27
-$0.20(-4.12%)
At close: 4:00 PM EST
$5.27
-$0.20(-4.12%)
Day’s Range― - ―
52-Week Range$3.81 - $5.70
Previous CloseN/A
Volume240.10K
Average Volume (3M)842.91K
Market Cap
$296.67M
Enterprise Value$12.03M
Total Cash (Recent Filing)$293.75M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Feb 11, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding59,096,630
10 Day Avg. Volume1,177,881
30 Day Avg. Volume842,906
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.52
Price to Sales (P/S)1.40
P/FCF Ratio-17.14
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$15.50Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$221.34M
Bulls Say, Bears Say
Bulls Say
Market PotentialThe motion sickness market opportunity may exceed $700M globally, according to Mordor Intelligence.
Product DevelopmentSuccessful development of an LAI version of iloperidone could revitalize the franchise even in the context of generic competition for the oral formulation.
Regulatory MilestonesThe FDA may elect to remove the partial clinical hold on tradipitant in motion sickness, thus clearing the path for Vanda to furnish additional long-term safety data to the agency in support of approval.
Bears Say
Clinical Data RequirementsIf Vanda is required to provide additional clinical data, this could be generated during 2026 and tradipitant could be the subject of an approval for treatment of motion sickness in 2027.
Financial PerformanceVanda reported a net loss of $0.38 per share, moderately wider than our forecast for a net loss of only $0.31 per share; this was mainly due to higher-than-anticipated operating expenses.
Regulatory ChallengesA decision to lift the partial clinical hold does not necessarily indicate agency willingness to approve tradipitant by the PDUFA date.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.81 and its highest was $5.70 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $296.67M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Feb 11, 2026 which is in 69 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Oct 29, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.053.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.96.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 59,096,630 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -20.148%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (194.12% Upside)
$15.50 (194.12% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 18.0%
Last 30 Days ▲ 18.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.52%
12-Months-Change
Fundamentals
Return on Equity
-16.72%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies to address high unmet medical needs. The company is primarily focused on the central nervous system and develops treatments for neurological and behavioral disorders. Its portfolio includes products like Hetlioz, which is used for the treatment of non-24-hour sleep-wake disorder, and Fanapt, an antipsychotic medication for the treatment of schizophrenia.
VNDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong commercial execution and pipeline advancements, with significant growth in Fanapt sales and strategic investments in infrastructure. However, the financial performance was marred by a significant net loss and increased operating expenses. Overall, the positives in sales and pipeline progression were balanced by financial challenges.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(194.12% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
15.94% Mutual Funds
9.52% Other Institutional Investors
54.39% Public Companies and
Individual Investors